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Abstract
Cyclic nucleotide phosphodiesterases (PDE) are the enzymes catalyzing the hydrolysis and
inactivation of the second messengers, cAMP and cGMP. Eleven PDE families are described to date,
and selective inhibitors of some PDEs families are currently used in clinic for treating cardiovascular
disorders, erectile dysfunction, and pulmonary hypertension. Isoforms of the PDE4 family are
involved in smooth muscle contraction and inflammation. PDE4 selective inhibitors are currently
in clinical trials for the treatment of diseases related to inflammatory disorders. Because of their
myorelaxant properties, we first examined their expression in human myometrium and uncover an
increased expression of one specific isoform, PDE4B2, in the near-term myometrium as compared
to myometrium in the nonpregnant state. Using human myometrial cells in culture, we
demonstrated that PDE4B2 can be induced by its own substrate, under the control of one of the
major utero-contractile agonists, PGE2, itself upregulated by the proinflammatory cytokine IL-1β.
Functionally, augmentation of global PDE4 activity decreases the ability of β-adrenergic agonists
(the most commonly used tocolytic drugs) to inhibit myometrial contraction at the end of
pregnancy and during pathophysiological situations, such as persistent intrauterine inflammation
which is a major cause of very preterm delivery. Currently exploring the anti-inflammatory
properties of PDE4 inhibitors in gestational tissues, we recently demonstrated the ability of these
drugs to block a persistent inflammatory response of the foetal membranes in Humans and to
prevent inflammation-driven preterm delivery and foetal demise in mice. These data open up a new
therapeutical strategy to prevent inflammation-induced preterm delivery and its sequelae in very
preterm infants.
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Background
Tea leaf has been used for 2,000 years in traditional Chi-
nese medicine for its therapeutical virtues before becom-
ing a traditional drink. One of its main active ingredients,
theophylline, is a selective inhibitor of cyclic nucleotide
phosphodiesterases (PDE), which hydrolyses the second
messengers, cAMP and cGMP. Eleven families of PDE are
described to date with different substrate preference,
kinetics and modulators [1]. Selective PDE inhibitors of
the type 3 and type 5 families are currently used in clinic,
respectively for cardiac disease, erectile dysfunction, and
pulmonary hypertension. PDE4 specifically hydrolyses
cAMP with high affinity and PDE4 inhibitors are highly
scrutinized because of their myorelaxant and anti-inflam-
matory properties.
PDE4 is the largest PDE family known to date, encoded by
four distinct genes, PDE4A-D, and generating more than
20 different isoforms in mammals by means of differen-
tial promoters and splicing. The PDE4s are further divided
in two main classes, the long and short forms that differ
with the presence or not of regulatory domains at their
amino-terminus [2,3] (Figure 1). In particular, the pres-
ence of a PKA-phosphorylation site well-conserved over
the PDE4 long forms activates these isoforms in a short-
term feedback loop. Conversely, cAMP- and hormonal-
sensitive promoters control the transcription of some of
the PDE4 short-forms, leading to a decrease in cAMP lev-
els after a sustained elevation of the cyclic nucleotide con-
tent. These regulations, as we describe below, are critical
to lessen the cAMP signalling in the utero-placental inter-
face at the end of pregnancy.
Results
We examined in human myometrium the expression of
the four genes of PDE4 in the nonpregnant state and near
term. A concurrent expression of the mRNAs of the four
genes with a predominance of the PDE4D and PDE4B
mRNAs and a weaker expression of PDE4A and PDE4C
genes was observed. Using semi-quantitative PCR and
Western blot, we observed, in near term myometrium, an
increase of the steady-state levels of PDE4B2 mRNA [4]
and protein [5], a short form product of the PDE4B gene.
We also explored functionally whether PDE4s are
involved in the control of the myometrial contractility.
Selective PDE4 inhibitors of the first (rolipram) and of the
most recent developed generation achieve a complete
relaxation of the myometrial strips, either in nonpregnant
or pregnant state [4-6]. Although the β-adrenergic ago-
nists, the most commonly used tocolytic agents, are able
to completely relax the nonpregnant myometrium, they
are unable to fully inhibit the pregnant uterine contrac-
tions. This phenomenon reflects the desensitization of the
β-adrenergic system at the end of the pregnancy [7]. Appli-
cation of a PDE4 inhibitor potentiates the effect of β-
mimetics, which then achieves a complete relaxation of
the pregnant strip [8] (Figure 2). It is worth noting that
PDE4 inhibitors do not potentiate the effect of or act in
synergy with β-adrenergic agonists on nonpregnant strips,
indicating an increased role of the PDE4s in the contrac-
tility of the pregnant state.
We explored in parallel the molecular mechanism of the
hormonal regulation of the PDE4 expression in primary
culture of myometrial cells. Like in the tissue of origin,
PDE4 is the major cAMP-hydrolyzing activity in these cells
and the four PDE4 genes are expressed. An increase in
intracellular cAMP concentration led to a significant
increase in cAMP PDE activity through the selective induc-
tion of the short forms of the PDE4B and PDE4D genes,
namely PDE4B2, PDE4D1 and PDE4D2 [9]. Hence, PDE4
upregulation provides a feedback mechanism by which
cells might adapt from sustained stimulation of the cAMP
pathway. We then shown that prostaglandin E2, one of the
major effectors of labour, can induce PDE4B2 and PDE4D
short forms, through a cAMP-dependent pathway, in the
myometrial smooth muscle cells [8]. This regulation may
occur during labour, when PGE2 concentration rises dra-
matically, but also in certain pathophysiological situa-
tions, with intrauterine inflammation, because we
observed that the proinflammatory cytokine IL1β, by
increasing PGE2concentration, is also able to induce
PDE4B2 [10]. Furthermore, impregnation of myometrial
strips with PGE2 leads to a heterologous desensitization of
the β-adrenergic system. This is translated by a decrease of
the relaxant strength of β-adrenergic agonists and is
reversed in the presence of PDE4 inhibitors [8]. Therefore,
a co-application of β-mimetics and PDE4 inhibitors may
greatly improve the efficiency of the tocolysis in case of
preterm labour.
Besides, because PDE4 activity is high in the amnion and
the chorion, we established that not only the myo-
metrium is a target for PDE4 inhibition but also the fetal
membranes. These data are of importance because amni-
ochorionic membranes are major sources of pro-inflam-
matory mediators and uterotonic agents. Indeed,
treatment of amniochorionic explants with the mem-
brane product of E. coli, the lipopolysaccharide (LPS),
induced synthesis of a pro-and anti-inflammatory
cytokine, TNFα and IL-10 respectively but also induced
synthesis of prostaglandins (PGs) and metalloproteases
(MMPs) [11]. In addition, PDE4 activity was independ-
ently increased by LPS treatment. On this model of
explants, we demonstrated that PDE4 selective inhibitors
diminished greatly the production of TNFα whereas they
enhanced the release of IL-10. They then decreased the
production of PGE2 and MMP9. Recently, we derived pri-
mary cells from the different cell types present in amnio-
chorionic membranes: amniotic epithelial cells,
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Potentiation of the relaxant effect of β-adrenergic agonist in the presence of a PDE4 selective inhibitor in pregnant myo-metriumFigure 2
Potentiation of the relaxant effect of β-adrenergic agonist in the presence of a PDE4 selective inhibitor in preg-
nant myometrium. Strips were mounted for isometric recording under 900 mg tension and after 2 h equilibration, contrac-
tile activity was assessed. Myometrial strip of either pregnant (A) or nonpregnant women (B) were preincubated with 3 × 10-
9M RP73401, a competitive selective PDE4 inhibitor (open circles) or saline (closed circles), 30 min prior the construction of 
the concentration-response to salbutamol. Results are expressed in percentage of maximal contraction at the end of the equi-
libration period. Strips from the same patients were subjected in parallel to treatments. Data are expressed as the mean ± SEM 
for strips isolated from myometrium of five different pregnant women and three different nonpregnant women. (Adapted from 
[8]).
Schematic organization of the PDE4 familyFigure 1
Schematic organization of the PDE4 family. PDE4s have a highly conserved globular catalytic domain, flanked by regula-
tory domains, such as the PDE4 signature domains UCR1 and UCR2 (for Upstream Conserved Regulatory domains), contain-
ing, for example, a PKA phosphorylation site. PDE4s are divided in short or long forms, defined by the absence or the presence 
of UCR1. Some examples of short and long forms, expressed or regulated in human myometrium are quoted. Short form 
products of PDE4B and PDE4D gene derived from a cAMP-sensitive intronic promoter. Long forms are usually constitutive.
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fibroblasts and chorionic epithelial cells, the choriotro-
phoblasts, which serve as models to identify signaling
pathways involved in a local inflammation.
Very recently, we demonstrated that PDE4 inhibition pre-
vents in vivo preterm delivery and fetal demise in mice
[12]. We adapted the inflammation-induced preterm
delivery model in mice established by Elovitz et al. [13].
On day 15 of gestation (term 20 days), LPS or saline was
injected in the uterus. Two hours after surgery, vehicle or
the PDE4 selective inhibitor, rolipram, was injected in the
peritoneal cavity and the frequency of preterm delivery
and the fetal demises were recorded 48 h post-surgery. In
the presence of rolipram, we observed that LPS-induced
preterm delivery is prevented as well as fetal demise, the
number of live pups in rolipram-LPS injected mice being
not statistically different from the control group (Figure
3). Moreover, we showed that the increased cytokine con-
centrations in the amniotic fluid of LPS-treated dams were
significantly reduced by the treatment with rolipram. We
evaluated by immunohistochemistry whether the tran-
scription factor of inflammation, NFκB, was translocated
in the nucleus in gestational tissues as an index of activa-
tion. Interestingly we found that, six hours after LPS injec-
tion, NFκB was located in the nucleus of a specific
placental cell, at the feto-maternal interface, the glycogen
trophoblast whereas this translocation was absent in tro-
phoblasts of dams treated with rolipram. No nuclear
translocation of NFκB was observed in myometrial cells.
Conclusion
These original studies uncover a new potential target, the
myometrial PDE4s, for tocolysis. In addition, PDE4
inhibitors are able to block the production of inflamma-
tory cytokines produced by myometrial and fetal explants
that may induce preterm delivery (Figure 4). Moreover the
in utero exposure to inflammation is a high risk factor of
neurological and respiratory disorders of the preterm
infant. Therefore, the combination of the myorelaxant
and anti-inflammatory properties of the PDE4 inhibitors
make these molecules particularly attractive for the pre-
vention of inflammation-induced preterm delivery and its
consequences on the premature infant.
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Summary of the effects of the PDE4 inhibition in gestational tissues in the cas  of intra-ut rine inflammationFig re 4
Summary of the effects of the PDE4 inhibition in ges-
tational tissues in the case of intra-uterine inflamma-
tion. Intrauterine inflammation leads to massive production 
of cytokines and chemokines, mainly by the fetal membranes, 
the chorio-decidua. Cytokines and chemokines start a feed-
forward mechanism and the production of uterotonic ago-
nists and metalloproteases in the chorio-decidua. These 
agents further digest the fetal membranes, contract the myo-
metrium, and soften the cervix, causing preterm labor. More-
over, inflammation of the amniotic cavity may target the 
developing brain and lungs of the fetus. We showed that 
PDE4 inhibition may directly in the human myometrium and 
indirectly by decreasing production of cytokines in the fetal 
membranes diminish uterine contraction and delay preterm 
delivery. Furthermore, by decreasing intrauterine inflamma-
tion, PDE4 inhibitors may favor a normal development of the 
fetal brain and lungs.
Inflammation-induced preterm delivery is prevented by rol-iprFigure 3
Inflammation-induced preterm delivery is prevented 
by rolipram. Delivered and undelivered dams were num-
bered 48 h after intrauterine injection of LPS or saline (A) 
and number of live pups per dams were recorded (B). The 
Fisher exact test was applied for comparison of preterm 
delivery rate in each group. ***p < 0.001 versus saline-vehicle 
group. For comparison of the number of live per dam, statis-
tical difference between groups was assessed by two-way 
ANOVA, followed by Student's t test, two tailed for unpaired 
samples.†††p < 0.001, versus the saline-vehicle group. 
(Adapted from [12]).
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